



NHS MEDICAL POLICY

Lutetium Lu-177 dotatate Medicine 2019-001

Lutetium Lu-177 dotatate (Lutathera) is the first FDA approved radiopharmaceutical drug. Treatment with Lutetium Lu-177 dotatate may be indicated when ALL the following are present:

1	The patient is an adult age 18 or more.
2	A gastroenteropancreatic neuroendocrine tumor (NET) has been diagnosed.
3	The patient has had disease progression during first-line somatostatin analogue therapy.
4	The neuroendocrine tumor (NET) has a reported Ki-67 of 20% or less.
5	The neuroendocrine tumor (NET) has somatostatin receptor expression, demonstrated by positive 68Ga-dotatate (Gallium 68, NETSPOT, etc.) imaging, PET-CT, PET-MRI, or somatostatin receptor scintigraphy.
6	The patient has adequate bone marrow, renal and hepatic function. This may be demonstrated by labs described as normal or adequate by the treating provider: CBC, BMP, CMP, LFT, INR.
7	Long-acting somatostatin analogs (lanreotide, octreotide) are not used for 4-6 weeks before each Lutetium Lu-177 dotatate treatment.
8	Any short acting octreotide used for symptom control is stopped 24 hours before each Lutetium Lu-177 dotatate treatment.
	Counseling about radiation safety precautions, exposure and other adverse effects is done.

SOURCES

1. UpToDate.com was accessed Jun 25, 2019: Lutetium Lu-177 dotatate: Drug information
2. National Institutes of Health. Lutetium Lu-177 dotatate package insert.
3. www.nccn.org National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology was accessed Jun 25, 2019: Neuroendocrine and adrenal tumors, Version 1.2019.
4. Brabander T, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0, Tyr3] octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res 2017;23(16):4617-4624.
5. Kong G et al. Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma. J Clin Endocrinol Metab 2017;102(9):3278-3287.
6. Strosberg J, et al. Phase 3 trial of 177Lu dotatate for midgut neuroendocrine tumors. N Engl J Med 2017;376:125-135.

CODE REFERENCE (This may not be a comprehensive list of codes to apply to this policy.)

A9699, C9031, C9399

POLICY HISTORY/REVISION INFORMATION

09/10/2020	Annual review and approval by UM Committee
09/10/2021	Annual review and approval by UM Committee
09/19/2022	Annual review and approval by UM Committee
08/23/2023	Annual review and approval by UM/QM Committee
08/23/2024	Annual review and approval by UM/QM Committee
06/27/2025	Annual review and approval by UM/QM Committee
06/25/2026	Annual review and approval by UM/QM Committee